Khoury G, Morel J, Combe B, et al. - An observational, retrolective study was undertaken to compare in real life the occurrence of anterior uveitis in patients with spondyloarthritis (SpA), including psoriatic arthritis (PsA), treated with the soluble-receptor etanercept (ETA) or monoclonal antibodies (mAbs). Between 2000 and 2014, researchers enrolled patients with SpA who were prescribed anti-TNF agents. This study recruited a total of 429 patients (302 with SpA and 127 with PsA); 203 received a mAb and 226 ETA as a first TNF-α inhibitor. Compared with mAb treatment, the risk of uveitis in patients with SpA does not seem to be greater with ETA in this observational study. Compared with the prescribed molecule, the occurrence of uveitis in patients receiving an anti-TNF-α agent seems linked more to the history of uveitis.